High risk of symptomatic cardiac events in childhood cancer survivors

Journal of Clinical Oncology

Volumn 30, Issue 13, 2012, Pages 1429-1437

  Van Der Pal, Helena J ^a   Van Dalen, Elvira C ^a   Van Delden, Evelien ^a   Van Dijk, Irma W ^a   Kok, Wouter E ^a   Geskus, Ronald B ^a   Sieswerda, Elske ^a   Oldenburger, Foppe ^a   Koning, Caro C ^a   Van Leeuwen, Flora E ^b   Caron, Huib N ^a   Kremer, Leontien C ^a  

^a EMMA CHILDREN S HOSPITAL   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE NONLYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AORTA STENOSIS; AORTA VALVE REGURGITATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CANCER SURVIVOR; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; CHILDHOOD CANCER; CONGENITAL HEART DISEASE; CONGESTIVE HEART FAILURE; DISEASE ASSOCIATION; EWING SARCOMA; FEMALE; GERM CELL TUMOR; HEART ARRHYTHMIA; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HODGKIN DISEASE; HUMAN; IRRADIATION; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE REGURGITATION; MITRAL VALVE STENOSIS; NEPHROBLASTOMA; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; OSTEOSARCOMA; PERICARDITIS; PRESCHOOL CHILD; PRIORITY JOURNAL; RADIATION DOSE; RISK FACTOR; SCHOOL CHILD; SOFT TISSUE SARCOMA; TRICUSPID VALVE REGURGITATION; TRICUSPID VALVE STENOSIS; VALVULAR HEART DISEASE; AGE; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; HEART DISEASE; HOSPITALIZATION; INCIDENCE; INFANT; KAPLAN MEIER METHOD; MULTIVARIATE ANALYSIS; NEOPLASM; NETHERLANDS; NEWBORN; PATIENT SELECTION; PROPORTIONAL HAZARDS MODEL; RADIATION INJURY; RADIATION RESPONSE; RADIOTHERAPY; RISK ASSESSMENT; SURVIVOR; TIME;

ADOLESCENT; ADULT; AGE FACTORS; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HEART DISEASES; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; KAPLAN-MEIER ESTIMATE; MALE; MULTIVARIATE ANALYSIS; NEOPLASMS; NETHERLANDS; PATIENT SELECTION; PROPORTIONAL HAZARDS MODELS; RADIATION INJURIES; RADIOTHERAPY; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SURVIVORS; TIME FACTORS; YOUNG ADULT;

EID: 84862983645     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.33.4730     Document Type: Article

References (37)

1. Gatta G, Zigon G, Capocaccia R, et al: Survival of European children and young adults with cancer diagnosed 1995-2002. Eur J Cancer 45:992-1005, 2009
2. Geenen MM, Cardous-Ubbink MC, Kremer LC, et al: Medical assessment of adverse health outcomes in long-term survivors of childhood cancer. JAMA 297:2705-2715, 2007 (Pubitemid 47001096)
3. Oeffinger KC, Mertens AC, Sklar CA, et al: Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 355:1572-1582, 2006 (Pubitemid 44547808)
4. Kremer LC, van Dalen EC, Offringa M, et al: Anthracycline-induced clinical heart failure in a cohort of 607 children: Long-term follow-up study. J Clin Oncol 19:191-196, 2001 (Pubitemid 32063496)
5. Reulen RC, Winter DL, Frobisher C, et al: Long-term cause-specific mortality among survivors of childhood cancer. JAMA 304:172-179, 2010
6. Mertens AC, Liu Q, Neglia JP, et al: Cause-specific late mortality among 5-year survivors of childhood cancer: The Childhood Cancer Survivor Study. J Natl Cancer Inst 100:1368-1379, 2008
7. Möller TR, Garwicz S, Barlow L, et al: Decreasing late mortality among five-year survivors of cancer in childhood and adolescence: A population-based study in the Nordic countries. J Clin Oncol 19:3173-3181, 2001 (Pubitemid 32591433)
8. Tukenova M, Guibout C, Oberlin O, et al: Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. J Clin Oncol 28:1308-1315, 2010
9. van Dalen EC, van der Pal HJ, Kok WE, et al: Clinical heart failure in a cohort of children treated with anthracyclines: A long-term follow-up study. Eur J Cancer 42:3191-3198, 2006 (Pubitemid 44872945)
10. Cardous-Ubbink MC, Heinen RC, Langeveld NE, et al: Long-term cause-specific mortality among five-year survivors of childhood cancer. Pediatr Blood Cancer 42:563-573, 2004 (Pubitemid 38669743)
11. Hudson MM, Rai SN, Nunez C, et al: Noninvasive evaluation of late anthracycline cardiac toxicity in childhood cancer survivors. J Clin Oncol 25:3635-3643, 2007 (Pubitemid 47372601)
12. Kremer LC, van der Pal HJ, Offringa M, et al: Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: A systematic review. Ann Oncol 13:819-829, 2002 (Pubitemid 34752678)
13. Kremer LC, van Dalen EC, Offringa M, et al: Frequency and risk factors of anthracycline-induced clinical heart failure in children: A systematic review. Ann Oncol 13:503-512, 2002 (Pubitemid 34461132)
14. Lipshultz SE, Lipsitz SR, Sallan SE, et al: Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol 23:2629-2636, 2005 (Pubitemid 46179451)
15. Mulrooney DA, Yeazel MW, Kawashima T, et al: Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: Retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 339:b4606, 2009
16. van der Pal HJ, van Dalen EC, Hauptmann M, et al: Cardiac function in 5-year survivors of childhood cancer: A long-term follow-up study. Arch Intern Med 170:1247-1255, 2010
17. Green DM, Grigoriev YA, Nan B, et al: Congestive heart failure after treatment for Wilms' tumor: A report from the National Wilms' Tumor Study group. J Clin Oncol 19:1926-1934, 2001 (Pubitemid 32702536)
18. Lipshultz SE, Colan SD, Gelber RD, et al: Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 324:808-815, 1991
19. Lipshultz SE, Lipsitz SR, Mone SM, et al: Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 332:1738-1743, 1995
20. Floyd JD, Nguyen DT, Lobins RL, et al: Cardiotoxicity of cancer therapy. J Clin Oncol 23:7685-7696, 2005 (Pubitemid 46291833)
21. Adams MJ, Lipsitz SR, Colan SD, et al: Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol 22:3139-3148, 2004 (Pubitemid 41103728)
22. van Dijk IW, Oldenburger F, Cardous-Ubbink MC, et al: Evaluation of late adverse events in long-term Wilms' tumor survivors. Int J Radiat Oncol Biol Phys 78:370-378, 2010
23. Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al: Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 109:1878-1886, 2007 (Pubitemid 46348183)
24. Heidenreich PA, Hancock SL, Lee BK, et al: Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol 42:743-749, 2003 (Pubitemid 37000197)
25. Hull MC, Morris CG, Pepine CJ, et al: Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy. JAMA 290:2831-2837, 2003 (Pubitemid 37509491)
26. van der Pal HJ, van Dalen EC, Kremer LC, et al: Risk of morbidity and mortality from cardiovascular disease following radiotherapy for childhood cancer: A systematic review. Cancer Treat Rev 31:173-185, 2005 (Pubitemid 40790389)
27. Hall EJ, Giaccia AJ: Time, dose, and fractionation in radiotherapy, in Hall EJ: Radiobiology for the Radiologist. Philadelphia, PA, Lippincott Williams & Wilkins, 2006, pp 378-397
28. Joiner MC, Bentzen SM: Fractionations: The linear-quadratic approach, in Joiner MC, van der Kogel A (eds): Basic Clinical Radiobiology. London, United Kingdom, Hodder Arnold, 2009, pp 102-117
29. Common Terminology Criteria for Adverse Events, version 3.0 (CTCAEv3.0), August 9, 2006. http://ctep.cancer.gov/protocolDevelopment/electronic- applications/docs/ctcaev3.pdf
30. Dignam JJ, Kocherginsky MN: Choice and interpretation of statistical tests used when competing risks are present. J Clin Oncol 26:4027-4034, 2008
31. Geskus RB: Cause-specific cumulative incidence estimation and the Fine and Gray model under both left truncation and right censoring. Biometrics 67:39-49, 2011
32. Putter H, Fiocco M, Geskus RB: Tutorial in biostatistics: Competing risks and multi-state models. Stat Med 26:2389-2430, 2007 (Pubitemid 46730255)
33. Satagopan JM, Ben-Porat L, Berwick M, et al: A note on competing risks in survival data analysis. Br J Cancer 91:1229-1235, 2004 (Pubitemid 39424779)
34. Hastie T, Sleeper L, Tibshirani R: Flexible covariate effects in the proportional hazards model. Breast Cancer Res Treat 22:241-250, 1992
35. [No authors listed]: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure: The SOLVD Investigators. N Engl J Med 325:293-302, 1991
36. [No authors listed]: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions: The SOLVD Investigators. N Engl J Med 327:685-691, 1992
37. Silber JH, Cnaan A, Clark BJ, et al: Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol 22:820-828, 2004 (Pubitemid 41103593)